Granted Patent
B2
US 12,661,345 · App. 19/386,124 · Granted Jun 23, 2026
Compositions for the treatment of hypertension
Assignee:
THE GEORGE INSTITUTE FOR GLOBAL HEALTH
A61K31/4422A61K31/277A61K31/382A61K31/40A61K31/4035A61K31/404A61K31/41A61K31/4178A61K31/4184A61K31/4418A61K31/495A61K31/517A61K31/549A61K31/554A61P9/12
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
Claims (18)
1 . A pharmaceutical composition for the treatment of hypertension, the pharmaceutical composition comprising:
(a) telmisartan;
(b) indapamide; and
(c) amlodipine besylate, wherein a dose of the telmisartan is about 30 milligrams (mg) to about 50 mg, a dose of the indapamide is about 1.875 mg to about 3.125 mg, and a dose of the amlodipine besylate is about EQ 3.75 mg base to about EQ 6.25 mg base;
wherein the pharmaceutical composition is free of a beta blocker; and
wherein the pharmaceutical composition comprises one or more cholesterol-lowering agents selected from ezetimibe, rosuvastatin, or a combination thereof.
2 . The pharmaceutical composition of claim 1 , wherein the dose of the telmisartan is about 40 mg.
3 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg.
4 . The pharmaceutical composition of claim 1 , wherein the dose of the amlodipine besylate is about EQ 5 mg base.
5 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg and the dose of amlodipine besylate is about EQ 5 mg base.
6 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg and the dose of the telmisartan is about 40 mg.
7 . The pharmaceutical composition of claim 1 , wherein the dose of the amlodipine besylate is about EQ 5 mg base and the dose of the telmisartan is about 40 mg.
8 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg, the dose of the amlodipine besylate is about EQ 5 mg base, and the dose of the telmisartan is about 40 mg.
9 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is provided in the form of a pill or a tablet.
10 . The pharmaceutical composition of claim 1 , wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
11 . The pharmaceutical composition of claim 9 , wherein a dose of the ezetimibe is about 10 mg, and wherein a dose of the rosuvastatin is about 10 mg.
12 . A method of treating at least one of hypertension and dyslipidemia in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 1 .
13 . A method of treating a combination of hypertension and dyslipidemia in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 1 .
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 17, 2026
From: RODGERS, ANTHONY; MACMAHON, STEPHEN
To: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
Reel/Frame 074401/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 17, 2026
From: RODGERS, ANTHONY; MACMAHON, STEPHEN
To: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
Reel/Frame 074401/0910 →
Continuity (15)
Continuation
18930405
· Oct 29, 2024
Continuation
18611260
· Mar 20, 2024
Continuation
18446257
· Aug 8, 2023
Continuation
PCTIB2018000083
· Jan 23, 2018
Provisional Application
62703802
· Jul 26, 2018
Provisional Application
62450324
· Jan 25, 2017
References Cited (151)
US 20030199492A1
· Scott
· 2003
[cited by applicant]
US 20040198789A1
· Leonardi et al.
· 2004
[cited by applicant]
US 20050187262A1
· Grogan et al.
· 2005
[cited by applicant]
US 20060110450A1
· Eisenreich
· 2006
[cited by applicant]
US 20060233876A1
· Jamerson et al.
· 2006
[cited by applicant]
US 20070191438A1
· Rohrer
· 2007
[cited by applicant]
US 20070293552A1
· Gorczynski
· 2007
[cited by applicant]
US 20080096866A1
· Woo et al.
· 2008
[cited by applicant]
US 20120115854A1
· Shetty et al.
· 2012
[cited by applicant]
US 20200030296A1
· Rodgers et al.
· 2020
[cited by applicant]
US 20230125076A1
· Rodgers et al.
· 2023
[cited by applicant]
CN 101450211A
· 2009
[cited by applicant]
CN 101618215A
· 2010
[cited by applicant]
CN 101966187A
· 2011
[cited by applicant]
CN 101966190A
· 2011
[cited by applicant]
CN 101966191A
· 2011
[cited by applicant]
CN 102225203A
· 2011
[cited by applicant]
CN 102327263A
· 2012
[cited by applicant]
CN 102327272B
· 2013
[cited by applicant]
CN 106074418A
· 2016
[cited by applicant]
CN 106310278A
· 2017
[cited by applicant]
EP 1272220B1
· 2006
[cited by applicant]
KR 20090057538A
· 2009
[cited by applicant]
WO WO03097045A1
· 2003
[cited by applicant]
WO WO2007098390A2
· 2007
[cited by applicant]
WO WO2007109037A2
· 2007
[cited by applicant]
WO WO2007146900A2
· 2007
[cited by applicant]
WO WO2009026517A2
· 2009
[cited by applicant]
WO WO2010127099A2
· 2010
[cited by applicant]
WO WO2011137734A1
· 2011
[cited by applicant]
WO WO2011149438A1
· 2011
[cited by applicant]
WO WO2014114627A1
· 2014
[cited by applicant]
WO WO2017054787A1
· 2017
[cited by applicant]
WO WO2018091967A1
· 2018
[cited by applicant]
WO WO2018138578A1
· 2018
[cited by applicant]
WO WO2020021341A1
· 2020
[cited by applicant]
Hong et al. (Clinical Therapeutics/vol. 41, No. 2, 2019 (Year: 2019).
[cited by examiner]
Calhoun, David A. et al., Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hpertension 54(1):32-9 (2009).
[cited by applicant]
ClinicalTrials.gov NCT02699645. Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (Trident). dated Jun. 26, 2016. Retrieved on Feb. 3, 2026 from ClinicalTrials.gov https://clinicaltrials.gov/stud…
[cited by applicant]
Co-pending U.S. Appl. No. 19/449,795, inventors Rodgers; Anthony et al., filed Jan. 15, 2026.
[cited by applicant]
Peng, Jie et al. Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure. Hypertens Res 38(2):123-31 (2015) Epub Oct. 2, 2014.
[cited by applicant]
Amlodipine Besylate Tablets. Greenstone Brand. NDS 19-787/S-042 (14 pgs) (2007).
[cited by applicant]
Andren et al. Enalapril with either a “very low” or “low” dose of hydrochlorothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertension I(suppl2):384-386 (…
[cited by applicant]
Anonymous. Assessment Report for Exforge HCT. European Medicines Agency. Evaluation of Medicines for Humane Use. Retrieved from the Internet: URL: https://www.ema.europa.eu/en/documents/assessment-report/exforge-hct-epa…
[cited by applicant]
Anonymous. Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial. ClinicalTrials.gov (Mar. 4, 2016). pp. 1-7. Retrieved from the Internet URL: https://clinicaltrials.gov/ct2/show/record/NCT02699645?v…
[cited by applicant]
Australian Institute of Health and Welfare 2017. Medicines for cardiovascular disease. Cat. No. CVD 80. Canberra: AIHW box 4 (36 pgs.) (2017).
[cited by applicant]
Beall et al. Could patents interfere with the development of a cardiovascular polypill? J Transl Med 14:242 (2016).
[cited by applicant]
Berge, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
[cited by applicant]
Bisoprolol/hydrochlorothiazide (Rx). Medscape Drugs & Diseases. Available at https://reference.medscape.com/drug/ziac-bisoprolol-hydrochlorothiazide-999421 (retrieved Dec. 18, 2020).
[cited by applicant]
Chou. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res 70(2):440-446 (2010).
[cited by applicant]
Chrysant, Steven G. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgrad Med 123(6):21-31 (2011).
[cited by applicant]
ClinicalTrials.gov Identifier: NCT02278471. The SCCS Polypill Pilot Trial, Record created Oct. 28, 2014. pp. 1-9. [retrieved on Jul. 9, 2024] Available at URL: https://clinicaltrials.gov/study/NCT02278471.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT02699645. Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Record created Jun. 26, 2016. pp. 1-4. [retrieved on Apr. 11, 2023] Available at URL: http…
[cited by applicant]
ClinicalTrials.gov Identifier: NCT02699645. Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (Trident), Record created Mar. 2, 2016. pp. 1-10. [retrieved on Jul. 9, 2024] Available at URL: https…
[cited by applicant]
ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin. [retrieved from internet on Nov. 11, 2019] URL:<https://clinicaltrials.gov/ct2/show/NCT03088254> First Posted Mar. 23…
[cited by applicant]
ClinicalTrials.gov. Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (Trident). U.S. National Library of Medicine; (May 4, 2017) https://clinicaltrials.gov/ct2/history/NCT02699645?V 5=View#Study…
[cited by applicant]
Co-pending U.S. Appl. No. 19/257,348, inventors Rodgers; Anthony et al., filed Jul. 1, 2025.
[cited by applicant]
Co-pending U.S. Appl. No. 19/341,633, inventors Rodgers; Anthony et al., filed Sep. 26, 2025.
[cited by applicant]
Crestor (rosuvastatin calcium) tablets drug label. Initial U.S. Approval: 2003. Reference ID: 3937746. May 2016.
[cited by applicant]
Diabetes Educational Services. Available at https://diabetesed.net/page/_files/ Antihypertensive-Meds-2012.pdf (3 pgs.) (2012).
[cited by applicant]
Dinicolantonio et al. Evidence-based diuretics: focus on chlorthalidone and indapamide . Future Cardiology 11:203-217 (2015).
[cited by applicant]
Drug Dosage. https://www.drugs.com/dosage/ (3 pgs.) (Accessed Apr. 2018).
[cited by applicant]
Emc+ Compendium. Latest Medicine Updates. https://www.medicines.org.uk/emc (2 pgs.) (Accessed Apr. 2018).
[cited by applicant]
Ershova A.K., Use of statins in patients with arterial hypertension. Russian Medical Journal 18(22):1389-1392 (2010) (English translation).
[cited by applicant]
Fishbane et al. Iron deficiency in non-dialysis chronic kidney disease. Kidney Int 75:752-754 (2009).
[cited by applicant]
Fletcher et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 99(6C):1E-35E (2007).
[cited by applicant]
Glezer et al. Comparative analysis of the effectiveness of diuretic in the treatment of arterial hypertension in women. The results of the Athena study. Problems of Women's Health 2(4):5-16 (2009).
[cited by applicant]
Higaki, Jitsuo et al. Effect of Hydrochlorothiazide in Addition to Telmisartan/amlodipine Combination for Treating Hypertensive Patients Uncontrolled with Telmisartan/amlodipine: a Randomized, Double-blind Study. Hypert…
[cited by applicant]
Huffman et al. Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety and Efficiency. JAMA 320(6):552-554 (2018).
[cited by applicant]
Huo et al. Effect of Simvastatin on Ankle Brachial Index in Middle and Old Age Patients with Hypertension. China Pharmacy 24(40):3795-3796 (2013) (English Abstract).
[cited by applicant]
Jadhav, Uday et al. Blood Pressure Control with a Single-pill Combination of Indapamide Sustained-release and Amlodipine in Patients with Hypertension: The Efficient study. PloS one 9(4):e92955, 1-6 (2014).
[cited by applicant]
Kenward et al. An improved approximation to the precision of fixed effects from restricted maximum likelihood. Computational Statistics & Data Analysis 53(7):2583-2595 (2009).
[cited by applicant]
Kenward et al. The use of baseline covariates in crossover studies. Biostatistics 11(1):1-17 (2010).
[cited by applicant]
Kharkevich. Pharmacology 3rd ed. Revised and supplemented, -M: Medicine p. 34 (1987).
[cited by applicant]
Kirichenko. The angiotensin II receptor antagonist candesartan in the arsenal of the therapist. Consilium Medicum 18:76-80 (2016).
[cited by applicant]
Krosnyuk et al. Pharmaceutical technology: Technology of dosage forms: textbook. for stud. higher. study institutions 2nd ed. stereo- M.: Publishing Center “Academia”. p. 6 (2006).
[cited by applicant]
Kuriyama et al. Renoprotective effect of triple therapy with low-dose angiotensis receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type-2 diabetic patients with overt nephropathy. Japanese Journal o…
[cited by applicant]
Law et al. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment 7(31):1-105 (2003).
[cited by applicant]
Law et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404):1427 (2003).
[cited by applicant]
Lee et al. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential …
[cited by applicant]
Li, Shaobo et al. Chapter 3: Strategies for administering drugs against hypertension in combination. Beijing, China: People's Military Medical Press (Eds.) (pp. 84-86) (2013) (w/English Translation).
[cited by applicant]
Liu et al. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med 28(20):2509-2530 (2009).
[cited by applicant]
Lozol® Indapamide Tablets. Aventis Pharmaceuticals Inc. (8 pgs.) (2005).
[cited by applicant]
Mahmud et al. Low-dose quadruple antihypertensive combination: more efficacious than individual agents—a preliminary report. Hypertension 49:272-275 (2007).
[cited by applicant]
Maladkar, Manish et al. Triple Drug Combination of Telmisartan, Amlodipine and Hydrochlorothiazide in the Treatment of Essential Hypertension. Open Journal of Internal Medicine 2(2):67-71 (2012).
[cited by applicant]
Mallion et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 13:657-664 (1…
[cited by applicant]
Mashkovsky M.D. Medicines: In 2 vols. V. 1.-M.: New Wave Publishing House LLC, 540:11 (2021).
[cited by applicant]
Micardis (Telmisartan) Tablets. Boehringer Ingelheim. NDA 20-850/S-022/S-023 (12 pgs.) (2009).
[cited by applicant]
Morozova et al. Clinical and economic aspects of the use of statins in patients with arterial hypertension with lipid metabolism disorders. Quality Clinical Practice 3:66-70 (2008).
[cited by applicant]
Neutel et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension. J Renin-Angiotensin_Aldosteone System 6(2):84-89 (2005).
[cited by applicant]
Nickenig. Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation 10:1013-1020 (2004).
[cited by applicant]
O'Brien et al. Ambulatory Blood Pressure Measurement. What Is the International Consensus? Hypertension 62(6):988-994 (2013).
[cited by applicant]
Ohira et al. Comparisons of Increasing Calcium Channel Blocker dose and Adding Thiazide Diuretic in Hypertensive Patients Given Medium-dose Angiotensin II Receptor Blocker and Amlodipine. Dokkyo Journal of Medical Scien…
[cited by applicant]
PCT/IB2017/001524 International Search Report and Written Opinion dated Apr. 17, 2018.
[cited by applicant]
PCT/IB2018/000083 International Search Report and Written Opinion dated Apr. 24, 2018.
[cited by applicant]
PCT/IB2019/000923 International Search Report and Written Opinion dated Dec. 2, 2019.
[cited by applicant]
Pinto et al. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovascular Res 39(1):77-88 (1998).
[cited by applicant]
Preiss, David. et al. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology 70(6):815-828 (2009).
[cited by applicant]
Rizos, Christos V. et al. Telmisartan: a multifaceted antihypertension drug. Current Medical Research and Opinion 32(8): 1397-1398 (2016).
[cited by applicant]
RxList. https://www.rxlist.com (5 pgs.) (Accessed Apr. 2018).
[cited by applicant]
Salam et al. TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol. Am Heart J. 167(2):127-132 (2014).
[cited by applicant]
Sharma. Dr. Reddy's launches combo drug for hypertension. Available at https://www.businesstoday.in/industry/pharma/story/dr-reddys-launches-combo-drug-for-hypertension-135017-2014-01-10 (2014).
[cited by applicant]
Shilov. III-generation calcium channel blockers in the treatment of arterial hypertension. Systemic hypertension 3:38-42 (2013).
[cited by applicant]
Skoularigis et al. Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am J Hypertens 8(10 Pt 1):10…
[cited by applicant]
Smith, David H.G. et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Pressure Monitoring 8(3):111-117 (2003).
[cited by applicant]
Spinler et al. ACE inhibitors versus ARBs: comparison of practice guidelines and treatment selection considerations. Formulary 41:274-284 (2006).
[cited by applicant]
Sureja, Dipen et al. Development And Validation of HPTLC Method for Simultaneous Estimation of Telmisartan and Indapamide in Pharmaceutical Solid Dosage Form. Journal of Chemical and Pharmaceutical Research 7(11):236-24…
[cited by applicant]
Tandon et al. Antihypertensive drug prescription patterns, rationality, and adherence to Joint National Committee-7 hypertension treatment guidelines among Indian postmenopausal women. J Mid-life Health 5(2):78-83 (2014…
[cited by applicant]
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT). Available at https://clinicaltrials.gov/ct2/show/record/NCT02699645 . First posted Mar. 4, 2016 (16 pgs).
[cited by applicant]
Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT). Available at https://clinicaltrials.gov/ct2/show/record/NCT02699645 . First posted Mar. 4, 2016 (Latest version Oct. 2, 2018) (9 pgs).
[cited by applicant]
U.S. Appl. No. 15/352,425 Office Action dated May 5, 2017.
[cited by applicant]
U.S. Appl. No. 15/352,425 Office Action dated Nov. 30, 2017.
[cited by applicant]
U.S. Appl. No. 15/919,923 Office Action dated Aug. 15, 2018.
[cited by applicant]
U.S. Appl. No. 15/919,923 Office Action dated Nov. 15, 2018.
[cited by applicant]
U.S. Appl. No. 16/393,774 Office Action dated Jan. 15, 2020.
[cited by applicant]
U.S. Appl. No. 16/523,230 Office Action dated Jan. 8, 2021.
[cited by applicant]
U.S. Appl. No. 16/523,230 Office Action dated Jun. 21, 2022.
[cited by applicant]
U.S. Appl. No. 16/523,230 Office Action dated Nov. 8, 2021.
[cited by applicant]
U.S. Appl. No. 17/014,358 Office Action dated Dec. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/932,982 Office Action dated Dec. 6, 2023.
[cited by applicant]
U.S. Appl. No. 18/446,268 Office Action dated Sep. 5, 2024.
[cited by applicant]
U.S. Appl. No. 19/073,585 Office Action dated Apr. 28, 2025.
[cited by applicant]
Vengerovsky, A.I. Pharmacological incompatibility. Bulletin of Siberian Medicine 3:49-56.
[cited by applicant]
Volpe, Massimo et al. Rationale for Triple Fixed-Dose Combination Therapy With an Angiotensin li Receptor Blocker, A Calcium Channel Blocker, and a Thiazide Diuretic. Vascular Health and Risk Management 8:371-380 (2012).
[cited by applicant]
Wald, David S. et al. Randomized Polypill Crossover Trial in People Aged 50 and Over. PLOS One 7(7):1-6 (2012).
[cited by applicant]
Wald et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122(3):290-300 (2009).
[cited by applicant]
Webster et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA 320(6)…
[cited by applicant]
Webster. Protocol changes to the TRIUMPH study. Am Heart J 191:e1 (2017).
[cited by applicant]
Zhao, Shuiping et al. (Eds.). Insights on Guidelines for Prevention and Treatment of Dyslipidemia in Chinese Adults (2nd ed.), “(II) Clinical Application”). People's Military Medical Press p. 231 (Jul. 2015) (w/English …
[cited by applicant]
Dr. Reddy's to market Optidoz, an anti-hypertension drug. https://www.thehindu.com/business/Industry/dr-reddys-to-market-optidoz-an-antihypertension-drug/article5567931.ece (updated May 14, 2016).
[cited by applicant]
U.S. Appl. No. 19/341,633 Office Action dated Dec. 10, 2025.
[cited by applicant]